Evaluation of Human Plasma Protein Binding of Trabectedin (Yondelis™, ET-743)

Jan H. Beumer(Johns Hopkins University), Olaf van Tellingen(Dutch Cancer Society), Luis López Lázaro(Dr. Reddy's Laboratories (Switzerland)), J. H. Beijnen(Erasmus MC Cancer Institute), Jan Schellens
Current Clinical Pharmacology
January 1, 2009
10.2174/157488409787236047
Cited by 12

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
|PubMed|2002|688